Outlook Therapeutics, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported net loss was USD 58.98 million compared to USD 66.05 million a year ago. Basic loss per share from continuing operations was USD 4.8 compared to USD 6.2 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.79 USD | -3.55% | -3.96% | -13.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.83% | 16Cr | |
+51.85% | 5.79TCr | |
+41.42% | 4.03TCr | |
-5.25% | 3.99TCr | |
-5.16% | 2.85TCr | |
+12.79% | 2.64TCr | |
-20.18% | 1.93TCr | |
+30.88% | 1.24TCr | |
+0.61% | 1.22TCr | |
+25.06% | 1.22TCr |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Outlook Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023